Merck stock holds firm as Keytruda drives revenue growth and late stage pipeline advances

Merck & Co. Inc. (ISIN US58933Y1055) stock continues to be shaped by its oncology franchise, with the cancer drug Keytruda remaining the primary earnings and cash flow engine. In the most recently reported quarter, Merck generated double digit revenue growth supported by higher Keytruda sales and steady vaccine demand, while investors are also watching the companys late stage pipeline and business development strategy as key inputs to the longer term outlook.

Keytruda revenue above 6 billion

In the first quarter of 2026, Merck reported that total company revenue reached about $16.1 billion, up roughly 9% compared with the same period a year earlier, according to the companys latest earnings materials. Oncology continued to be the main growth driver. Keytruda, Mercks immuno oncology therapy that is already approved across a wide range of tumor types, contributed more than $6.0 billion of revenue in the quarter, representing an increase of roughly 15% versus the prior year period as reported by the company. The performance underscores how dependent Merck remains on this single asset but also how resilient demand is in both earlier and later lines of therapy across indications.

Management highlighted that the growth in Keytruda was driven by increased penetration in earlier stage cancers such as adjuvant and neoadjuvant settings, as well as continued uptake in metastatic indications. In practical terms, that means the medicine is being used more often and earlier in the treatment algorithm, which supports higher volumes even in competitive markets like non small cell lung cancer. The company has emphasized that Keytrudas patent exclusivity in the United States runs into the early 2030s, providing several more years of pricing power in its largest market.

Overall revenue grows high single digits

Across the wider portfolio, Merck recorded high single digit revenue growth in the first quarter of 2026 compared with the same quarter in 2025. Pharmaceutical segment sales, which include oncology, vaccines, hospital acute care and other therapeutic areas, increased by a high single digit percentage, driven not only by Keytruda but also by higher volumes for vaccine brands. The animal health division contributed a smaller but still meaningful portion of group revenue, with modest year on year growth helped by demand for companion animal products.

Importantly for investors, Merck also converted a good portion of this revenue into bottom line earnings. Adjusted earnings per share in the quarter came in in the mid one dollar range, which marked an increase of around 10% compared with the prior year period based on the companys reporting. The margin performance benefited from operating leverage on higher sales, partially offset by continued spending on research and development and promotion for newer indications.

Guidance underpinned by oncology and vaccines

For the full year 2026, Merck has guided to revenue growth in the high single digit to low double digit percentage range, underpinned by the continued expansion of Keytruda and steady demand for its vaccines portfolio. The guidance implies that management expects to maintain or slightly accelerate the top line growth rate versus 2025, assuming no major currency swings or unexpected generic competition in key products. From an earnings perspective, the company targets adjusted earnings per share growth that is roughly in line with or slightly above revenue growth, reflecting a relatively stable margin profile.

Analysts who follow the stock typically compare Mercks valuation to other large cap biopharmaceutical companies with strong oncology franchises. With Keytruda still growing at a double digit rate from a high base and a multi year patent runway ahead, the drug is often viewed as supporting a premium multiple relative to peers that lack similar growth visibility. At the same time, the companys heavy reliance on one product for a large portion of its revenue and profit remains a central part of the investment debate and a key reason why pipeline execution and business development activity are so closely watched.

Keytruda expands into earlier settings

Keytrudas growth is not just a volume story in existing indications. Merck has been investing heavily in clinical trials designed to move the drug into earlier lines of therapy and additional tumor types. Each successful trial and subsequent regulatory approval can add incremental revenue and extend the asset lifecycle, especially when approvals involve adjuvant or neoadjuvant use in earlier stage cancers where patients tend to be treated for longer durations.

In several recent regulatory updates, health authorities in major markets have approved new Keytruda indications in areas such as adjuvant treatment for certain high risk early stage cancers and combinations with chemotherapy in first line metastatic settings. While the exact contribution of each new indication to 2026 revenue is difficult to isolate, the aggregate effect has supported the roughly 15% year on year sales growth the drug recorded in the latest quarter. Over time, a broader label portfolio may also help cushion the impact of eventual biosimilar or competitive pressures in any single indication.

Pipeline and business development complement organic growth

Beyond Keytruda, Merck has stressed that its research and development pipeline includes multiple late stage assets that could become meaningful revenue contributors later in the decade. These include additional oncology programs that may either complement Keytruda or target different mechanisms, as well as candidates in cardiovascular and immunology. The company regularly discloses the number of phase three programs in its pipeline, which remains in the double digits, providing a diversified set of potential future launches.

Merck also continues to supplement internal research with external business development transactions. Over the past few years, it has executed acquisitions and collaborations aimed at bolstering its oncology, immunology and cardiovascular portfolios, with transaction sizes ranging from several hundred million dollars into the multi billion dollar range. While individual deal metrics vary, the strategic goal is to ensure that the revenue base remains diversified once Keytruda eventually faces more intense competition later in the 2030s.

Dividend and cash generation support returns

For income oriented investors, Merck has a long standing record of paying regular dividends. In 2025, the company distributed dividends that, on an annualized basis, represented a payout ratio in the range of forty to fifty percent of adjusted earnings. That left adequate room for reinvestment in research, capital expenditures and bolt on acquisitions while still providing shareholders with a tangible cash return. With adjusted earnings per share growing around 10% year on year in the latest reported quarter, the dividend capacity appears supported by underlying profit growth.

Merck also generates substantial operating cash flow, which management uses not only for dividends but also for share repurchases and debt reduction when appropriate. The balance sheet carries investment grade credit ratings and a leverage profile that is manageable compared with peers, giving the company flexibility to pursue further business development if the right opportunities arise.

Keytruda immunotherapy underpins oncology franchise

As a product, Keytruda is central to Mercks strategy in oncology. The drug, a programmed death receptor 1 (PD 1) blocking antibody, works by helping the immune system recognize and attack cancer cells. It has become a standard of care in multiple tumor types, including non small cell lung cancer, melanoma, head and neck cancer, and certain types of gastrointestinal and genitourinary cancers. The broad range of indications and lines of therapy has allowed Merck to build a franchise that spans both advanced metastatic disease and earlier stage treatment settings.

Revenue from Keytruda, which surpassed $6.0 billion in the most recently reported quarter, reflects not only the drugs clinical profile but also Mercks commercial execution. The company has built extensive relationships with oncologists, treatment centers and payers to ensure access and reimbursement across markets. For investors looking at Merck stock, the continued performance and evolving label of Keytruda are among the most important operational metrics, both because of the current revenue contribution and because of the implications for the companys growth trajectory beyond 2030.

Merck stock and market snapshot

Merck stock trades on the New York Stock Exchange under the ticker MRK as part of the Dow Jones Industrial Average and the S&P 500, positioning it among the most widely followed healthcare names globally. The companys market capitalization stands in the large cap range, reflecting investor expectations for continued cash generation from Keytruda, steady contribution from vaccines and animal health, and eventual revenue from late stage pipeline assets. Over the past year, the share price has generally tracked the prospects for the oncology business, reacting to clinical trial readouts, regulatory decisions and changes in industry valuations.

For many portfolio managers, Merck occupies a role as a core healthcare holding with a blend of growth and income characteristics. The combination of high single digit to low double digit expected revenue growth, around 10% adjusted earnings growth in the latest quarter, and a dividend payout ratio around mid range of earnings can be attractive relative to the broader pharmaceutical peer group. At the same time, concentration risk in Keytruda and potential pricing pressures in the United States and abroad are important counterpoints when assessing the risk reward profile of Merck stock.